BE704262A - - Google Patents
Info
- Publication number
- BE704262A BE704262A BE704262DA BE704262A BE 704262 A BE704262 A BE 704262A BE 704262D A BE704262D A BE 704262DA BE 704262 A BE704262 A BE 704262A
- Authority
- BE
- Belgium
- Prior art keywords
- adamantane
- amino
- salt
- pharmacologically acceptable
- organic acid
- Prior art date
Links
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 13
- 150000007524 organic acids Chemical class 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- QZWNXXINFABALM-UHFFFAOYSA-N adamantan-2-amine Chemical compound C1C(C2)CC3CC1C(N)C2C3 QZWNXXINFABALM-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 230000000840 anti-viral effect Effects 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 150000001447 alkali salts Chemical class 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000001508 potassium citrate Substances 0.000 claims description 3
- 229960002635 potassium citrate Drugs 0.000 claims description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 3
- 235000011082 potassium citrates Nutrition 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 159000000011 group IA salts Chemical class 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims 2
- 239000011736 potassium bicarbonate Substances 0.000 claims 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims 2
- FKGQBHBDIDTCOF-UHFFFAOYSA-N adamantene amine Chemical compound C1C(C2)CC3CC2=CC1(N)C3 FKGQBHBDIDTCOF-UHFFFAOYSA-N 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- -1 2-amino adamantene Chemical compound 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000220304 Prunus dulcis Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- WLDWDRZITJEWRJ-UHFFFAOYSA-N adamantan-2-amine;hydron;chloride Chemical compound Cl.C1C(C2)CC3CC1C(N)C2C3 WLDWDRZITJEWRJ-UHFFFAOYSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940052761 dopaminergic adamantane derivative Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000019275 potassium ascorbate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL6613588A NL6613588A (de) | 1966-09-27 | 1966-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE704262A true BE704262A (de) | 1968-03-25 |
Family
ID=19797773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE704262D BE704262A (de) | 1966-09-27 | 1967-09-25 |
Country Status (3)
| Country | Link |
|---|---|
| BE (1) | BE704262A (de) |
| ES (1) | ES345432A1 (de) |
| NL (1) | NL6613588A (de) |
-
1966
- 1966-09-27 NL NL6613588A patent/NL6613588A/xx unknown
-
1967
- 1967-09-25 ES ES345432A patent/ES345432A1/es not_active Expired
- 1967-09-25 BE BE704262D patent/BE704262A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES345432A1 (es) | 1969-02-01 |
| NL6613588A (de) | 1968-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0233853B1 (de) | Brausepaare, H2-Antagonisten von Histamin enthaltende Brausemischungen und Verfahren zu ihrer Herstellung | |
| BE1005691A4 (fr) | Composition pharmaceutique a base de ranitidine et son procede de preparation. | |
| EP0673245B1 (de) | Brausemischungen enthaltend ibuprofen und verfahren | |
| EP0693926B1 (de) | Arzneizubereitung zum Herstellen eines stabilisierten Pulvers das eine Kombination aus Acetylsalicylsäure und Metoclopramid als Wirkstoff enthält | |
| EP1543826B1 (de) | Konzentrierte wässrige Ambroxollösung | |
| FR2661610A1 (fr) | Nouvelle forme lyophilisee de la diosmine et sa preparation. | |
| BE704262A (de) | ||
| EP0541874A1 (de) | Diosmin enthaltende Arzneimittel | |
| JPH0152366B2 (de) | ||
| BE1004182A3 (fr) | Compositions pharmaceutiques contenant un compose a activite agoniste selective aux recepteurs analogues a la 5-ht1. | |
| WO1996033743A1 (fr) | Compositions pulverulentes et solubles dans l'eau et leurs applications | |
| EP1137420B1 (de) | Verwendung einer kombination aus einem purin und einem no-donor zur behandlung und prophylaxe sexueller funktionsstörungen | |
| FR2673842A1 (fr) | Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4. | |
| MC1281A1 (fr) | Agents diuretiques | |
| EP1052993A1 (de) | Zusammensetzung von alpha-adrenergischer antagonisten mit stickstoffoxyddonoren zur behandlung von sexualfunktionsstörungen bei frauen | |
| FR2823M (de) | ||
| FR2741532A1 (fr) | Nouvelles compositions pharmaceutiques a action antimigraineuse et leur mode de preparation | |
| FR3160103A1 (fr) | Composition pharmaceutique de metformine pour administration orale. | |
| FR2715564A1 (fr) | Composition pharmaceutique contenant de la N-acétyl-cystéine. | |
| BE887220A (fr) | Compositions antitumeurs | |
| FR2507084A1 (fr) | Composition antibiotique pour l'administration de la phosphomycine sous forme de comprimes a dissolution lente | |
| FR2620619A1 (fr) | Nouveau procede pharmaceutique pour obtenir une formule unique pour des usages et une securite therapeutiques nouveaux et meilleurs | |
| CH660189A5 (fr) | Sels de dioxyde de benzothiazine cristallin et compositions pharmaceutiques les contenant. | |
| BE882259A (fr) | Compositions pharmaceutiques synergiques et leur procede de preparation | |
| FR2471190A1 (fr) | Composition therapeutique utile dans le traitement de la toux comprenant un moyen antitussif, un moyen antispasmodique, un moyen antihistaminique et un moyen expectorant |